The current financial score of Clearpoint Neuro Inc is 6.22. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 10.88M, representing a year-over-year increase of 18.07%, while its net profit experienced a year-over-year increase of 94.23%.
The current valuation score of Clearpoint Neuro Inc is 9.11. Its current P/E ratio is -14.50, which is -65.39% below the recent high of -5.02 and -155.13% above the recent low of -36.98.
The current earnings forecast score of Clearpoint Neuro Inc is 9.00. The average price target is 23.50, with a high of 25.00 and a low of 22.00.
The current price momentum score of Clearpoint Neuro Inc is 4.72. Currently, the stock price is trading between the resistance level at 16.60 and the support level at 12.81, making it suitable for range-bound swing trading.
The current institutional shareholding score of Clearpoint Neuro Inc is 5.00. The latest institutional shareholding proportion is 52.78%, representing a quarter-over-quarter increase of 23.25%.
The current risk assessment score of Clearpoint Neuro Inc is 4.51. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.